Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25684315 | 0.85 | NR1H2 (0.40) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL21541673 | 0.85 | NR1H2 (0.36) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20355294 | 0.84 | NR1H2 (0.38) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31094785 | 0.80 | USP2 (0.44) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15543924 | 0.80 | EPHX1 (0.40) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL25484581 | 0.79 | USP2 (0.41) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL26099571 | 0.79 | USP2 (0.41) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL25187478 | 0.79 | USP2 (0.41) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1086226 | 0.77 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL15415766 | 0.76 | USP2 (0.41) | NR1H2MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567030-B1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | MEDSHINE DISCOVERY INC. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3567030-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | EGFR, ERBB2, ERBB4 | NR1H2 2047/4885MEN1 3587/4885ALDH1A1 3390/4885 |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | EGFR, ERBB2, ERBB4 | NR1H2 2047/4885MEN1 3587/4885ALDH1A1 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.